BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Alex Straumann  1     Alfredo J. Lucendo  2     Stephan Miehlke  3     Michael Vieth  4     Christoph Schlag  5     Luc Biedermann  6     Cecilio Santander  7     Christoph Schmöcker  8     Ahmed Madisch  9     Jamal Hayat  10     Arjan Bredenoord  11     Stefan Schubert  12     Ralph Mueller  13     Roland Greinwald  13     Alain M. Schoepfer  14     Stephen E. Attwood  15     Petr Hruz  16     Constanza Ciriza De Los Ríos  17     Ulrike von Arnim  18    
1 Swiss EoE Research Network, Olten, Switzerland
2 Hospital General de Tomelloso, Tomelloso, Spain
3 Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany
4 Klinikum Bayreuth, Bayreuth, Germany
5 Klinikum rechts der Isar - TU München, München, Germany
6 University Hospital Zurich, Zurich, Switzerland
7 Hospital Universitario de la Princesa, Madrid, Spain
8 Sana Klinikum Lichtenberg, Berlin, Germany
9 CRH Clinic Hannover, Hannover, Germany
10 St. George`s University Hospitals NHS Trust, London, United Kingdom
11 Academisch Med. Centrum Amsterdam, Amsterdam, Netherlands
12 Gastroenterologist in Private Practice, Berlin, Germany
13 Dr. Falk Pharma GmbH, Freiburg, Germany
14 University Hospital (CHUV), Lausanne, Switzerland
15 Durham University, North Tyneside, United Kingdom
16 University Hospital Basel, Basel, Switzerland
17 Hospital 12 de Octubre, Madrid, Spain
18 University Hospital Magdeburg, Madgeburg, Germany

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing